Condition: Brain Tumors · Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
This study focuses on rare brain tumors, which are heterogeneous entities with different morphological, biological, and clinical characteristics. Due to their rarity, many of these tumors fall under the RARECARE definition of rare tumors. The main objective of the study is to standardize care models and pathways for patients with rare brain tumors, using Artificial Intelligence (AI) and Machine Learning (ML) techniques to identify specific predictors of postoperative outcomes. The study includes both retrospective and prospective phases, with the collection of clinical, cognitive, and psychological data at various time points. Patients will undergo an early neuro-cognitive rehabilitation program using the RehaCom software, which will be conducted at home. The goal is to improve the quality of life and care for patients through a multidisciplinary and innovative approach.
This description comes directly from the study's public registry record.
GIORGIA CAMARDA, Master's degree · +23 02 2394 · giorgia.camarda@istituto-besta.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Istituto Neurologico Carlo Besta | Milan, PA, Italy | Recruiting |
| ASL 1 Abruzzo Avezzano-Sulmona-L'Aquila | L’Aquila, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06878469